ARTICLE | Company News
Allergan, Senju deal
May 31, 2004 7:00 AM UTC
AGN granted Senju an exclusive license to develop and market Lumigan bimatoprost ophthalmic solution - 0.03%. Senju is responsible for the development and commercialization of Lumigan in Japan and wi...